New protocol aims to plug deadly hole in esophageal cancer care
NCT ID NCT07353541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a standardized care plan for esophageal fistula, a severe complication of advanced esophageal cancer where a hole forms between the esophagus and windpipe or chest. The plan includes sealing the hole with stents, antibiotics, nutrition support, and further cancer therapy. Researchers will track survival and how many patients can resume cancer treatment. The study aims to enroll 32 adults with newly diagnosed fistula.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Standardized management protocol (stents, anti-infectives, nutrition, etc.)
- What this could lead to
- If successful, this protocol could help more patients with this serious complication survive longer and receive further cancer treatment.
- What could go wrong
- This is a small, early-stage study with no control group, so results may not apply broadly. The condition is life-threatening, and the protocol may not improve outcomes for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL FISTULA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return